FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992947462> ?p ?o ?g. }

• W1992947462 endingPage "610" @default.
• W1992947462 startingPage "601" @default.
• W1992947462 abstract "Glioblastoma is the most common and aggressive primary brain tumor. Glioma stem cells (GSCs) are relatively resistant to chemo-radiotherapy and are responsible for tumor progression and the recurrence of glioblastomas after conventional therapy. Thus, the control of the GSC population is considered key to realizing long-term survival of glioblastoma patients. Here, we identified that resveratrol significantly reduced the self-renewal and tumor-initiating capacity of patient-derived GSCs. Furthermore, resveratrol promoted Nanog suppression via proteasomal degradation, which was inhibited by MG132, a proteasome inhibitor. p53 activation is an important factor in Nanog suppression and treatment with resveratrol was also found to activate the p53/p21 pathway. Importantly, inhibition of Nanog by siRNA provoked inhibitory effects on both the self-renewal and tumor-forming capacity of GSCs. Our findings indicate that Nanog is an essential factor for the retention of stemness and may contribute to the resveratrol-induced differentiation of GSCs. Our results also suggest that targeting GSCs via the p53-Nanog axis, with resveratrol for instance, could be a therapeutic strategy against glioblastoma." @default.
• W1992947462 created "2016-06-24" @default.
• W1992947462 creator A5003456909 @default.
• W1992947462 creator A5020134754 @default.
• W1992947462 creator A5036529017 @default.
• W1992947462 creator A5037577584 @default.
• W1992947462 creator A5038183052 @default.
• W1992947462 creator A5057687484 @default.
• W1992947462 creator A5063521263 @default.
• W1992947462 creator A5067619689 @default.
• W1992947462 creator A5081487939 @default.
• W1992947462 creator A5086562781 @default.
• W1992947462 date "2013-07-01" @default.
• W1992947462 modified "2023-09-29" @default.
• W1992947462 title "Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells" @default.
• W1992947462 cites W1976878409 @default.
• W1992947462 cites W1980421241 @default.
• W1992947462 cites W1982649435 @default.
• W1992947462 cites W1990361620 @default.
• W1992947462 cites W1993347240 @default.
• W1992947462 cites W1999155906 @default.
• W1992947462 cites W2001544973 @default.
• W1992947462 cites W2003917628 @default.
• W1992947462 cites W2004607502 @default.
• W1992947462 cites W2019199359 @default.
• W1992947462 cites W2019768326 @default.
• W1992947462 cites W2023759379 @default.
• W1992947462 cites W2025183726 @default.
• W1992947462 cites W2026379260 @default.
• W1992947462 cites W2029669343 @default.
• W1992947462 cites W2036044314 @default.
• W1992947462 cites W2048527809 @default.
• W1992947462 cites W2051863666 @default.
• W1992947462 cites W2060551076 @default.
• W1992947462 cites W2063827609 @default.
• W1992947462 cites W2069228161 @default.
• W1992947462 cites W2080838269 @default.
• W1992947462 cites W2081620485 @default.
• W1992947462 cites W2096287682 @default.
• W1992947462 cites W2097308038 @default.
• W1992947462 cites W2102085111 @default.
• W1992947462 cites W2106365104 @default.
• W1992947462 cites W2107575419 @default.
• W1992947462 cites W2112479759 @default.
• W1992947462 cites W2117623697 @default.
• W1992947462 cites W2123509170 @default.
• W1992947462 cites W2126851387 @default.
• W1992947462 cites W2129448796 @default.
• W1992947462 cites W2129644533 @default.
• W1992947462 cites W2133326191 @default.
• W1992947462 cites W2140152239 @default.
• W1992947462 cites W2145321451 @default.
• W1992947462 cites W2150085213 @default.
• W1992947462 cites W2154587590 @default.
• W1992947462 cites W2158681922 @default.
• W1992947462 cites W2159640574 @default.
• W1992947462 cites W2166556978 @default.
• W1992947462 cites W2167167418 @default.
• W1992947462 cites W2167414381 @default.
• W1992947462 cites W2167648407 @default.
• W1992947462 cites W2171741391 @default.
• W1992947462 doi "https://doi.org/10.1016/j.scr.2013.04.004" @default.
• W1992947462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23651583" @default.
• W1992947462 hasPublicationYear "2013" @default.
• W1992947462 type Work @default.
• W1992947462 sameAs 1992947462 @default.
• W1992947462 citedByCount "66" @default.
• W1992947462 countsByYear W19929474622013 @default.
• W1992947462 countsByYear W19929474622014 @default.
• W1992947462 countsByYear W19929474622015 @default.
• W1992947462 countsByYear W19929474622016 @default.
• W1992947462 countsByYear W19929474622017 @default.
• W1992947462 countsByYear W19929474622018 @default.
• W1992947462 countsByYear W19929474622019 @default.
• W1992947462 countsByYear W19929474622020 @default.
• W1992947462 countsByYear W19929474622021 @default.
• W1992947462 countsByYear W19929474622022 @default.
• W1992947462 countsByYear W19929474622023 @default.
• W1992947462 crossrefType "journal-article" @default.
• W1992947462 hasAuthorship W1992947462A5003456909 @default.
• W1992947462 hasAuthorship W1992947462A5020134754 @default.
• W1992947462 hasAuthorship W1992947462A5036529017 @default.
• W1992947462 hasAuthorship W1992947462A5037577584 @default.
• W1992947462 hasAuthorship W1992947462A5038183052 @default.
• W1992947462 hasAuthorship W1992947462A5057687484 @default.
• W1992947462 hasAuthorship W1992947462A5063521263 @default.
• W1992947462 hasAuthorship W1992947462A5067619689 @default.
• W1992947462 hasAuthorship W1992947462A5081487939 @default.
• W1992947462 hasAuthorship W1992947462A5086562781 @default.
• W1992947462 hasBestOaLocation W19929474621 @default.
• W1992947462 hasConcept C104317684 @default.
• W1992947462 hasConcept C107459253 @default.
• W1992947462 hasConcept C145103041 @default.
• W1992947462 hasConcept C207701140 @default.
• W1992947462 hasConcept C27740335 @default.
• W1992947462 hasConcept C2776816829 @default.
• W1992947462 hasConcept C2778227246 @default.
• W1992947462 hasConcept C2778367456 @default.

• next